

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model
Run on: November 6, 2004, 19:23:00 ; Search time 62.6562 Seconds
(without alignments)
28.627 Million cell updates/sec

Title: US-10-618-644-5
Perfect score: 27
Sequence: 1 TPRVF 5
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5
Searched: 200273 seqs, 358729299 residues
Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A.Geneseq_23Sep04:*
1: geneseqp1980s:*
2: geneseqp1980s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	27	100.0	5	5	ABB81807 Soybean a
2	27	100.0	7	2	Aar13594 Angiotens
3	27	100.0	14	4	Aab64509 Gene 25 h
4	27	100.0	49	4	Aam17754 Peptide #
5	27	100.0	49	4	Abb36778 Peptide #
6	27	100.0	49	4	Aam30265 Peptide #
7	27	100.0	49	4	Abb31563 Peptide #
8	27	100.0	49	4	Abb22104 Protein #
9	27	100.0	49	4	Aam69928 Human bon
10	27	100.0	49	4	Aam57526 Human bra
11	27	100.0	49	4	Abg51626 Human liv
12	27	100.0	49	4	Aam05410 Peptide #
13	27	100.0	49	5	Abg39558 Human pep
14	27	100.0	65	3	Ag22500 Arabidops
15	27	100.0	70	4	Aam81712 Human hae
16	27	100.0	70	4	Aam81457 Human hae
17	27	100.0	105	4	Aau58073 Propionib
18	27	100.0	105	6	Abm54592 Propionib
19	27	100.0	106	3	Ag22499 Arabidops
20	27	100.0	112	4	Aac03893 Human pol
21	27	100.0	113	3	Ag22498 Arabidops
22	27	100.0	115	4	Aam81529 Human hae
23	27	100.0	115	4	Aam81079 Human hae
24	27	100.0	115	4	Aam81657 Human hae
25	27	100.0	115	4	Aam81175 Human hae

26	27	100.0	143	4	AAO00557	Aao00557 Human pol
27	27	100.0	167	5	ADK34674	Adk34674 Novel hum
28	27	100.0	186	7	ADC32883	Adc32883 Human nov
29	27	100.0	206	2	AAW17978	Aaw17978 dTDP-4-ke
30	27	100.0	207	4	ABB06925	Abb06925 Micromono
31	27	100.0	207	6	ABP99315	Abp99315 Orthosomy
32	27	100.0	214	6	ABR01485	Abro1485 Human ant
33	27	100.0	237	4	AAG93005	Agg93005 C glutami
34	27	100.0	257	7	ADD13575	Add13575 C. glutam
35	27	100.0	275	3	AGS1538	Aggs1538 Arabidops
36	27	100.0	275	3	AGS1538	Aggs1538 Arabidops
37	27	100.0	275	3	AGS1538	Aggs1538 Arabidops
38	27	100.0	316	3	AGS1537	Aggs1537 Arabidops
39	27	100.0	316	3	AGS1537	Aggs1537 Arabidops
40	27	100.0	324	3	AGS1537	Aggs1537 Arabidops
41	27	100.0	332	5	ABG96259	Abg96259 Maize per
42	27	100.0	347	5	ABG96251	Abg96251 Maize per
43	27	100.0	362	7	ABO68987	Abog68987 Pseudomon
44	27	100.0	376	7	ADC31181	Adc31181 Human nov
45	27	100.0	376	7	ADM04333	Adm04333 Human pro

ALIGNMENTS

RESULT 1
ABB81807
ID ABB81807 standard; peptide; 5 AA.
XX
AC ABB81807;
XX
DT 23-SEP-2002 (first entry)
XX
DE Soybean angiotensin converting enzyme inhibitory peptide #5.
XX
KW Soybean; angiotensin converting enzyme inhibitor; hypertension;
KW hypotensive; taste.
XX
OS Glycine max.
XX
PN WO20025546-A1.
XX
PD 18-JUL-2002.
XX
PF 15-JAN-2002; 2002WO-JP000194.
XX
PR 16-JAN-2001; 2001JP-00007400.
PR 04-OCT-2001; 2001JP-00308974.
XX
PA (AJIN) AJINOMOTO CO INC.
XX
PI Kodera T, Nio N;
XX
DR WPI; 2002-520117/55.
XX
PT Peptides, useful as hypotensive agents or in health foods.
XX
PS Claim 1; Page 19; 43pp; Japanese.
XX
CC The invention relates to a novel set of peptides and their salts. The
CC peptides of the invention have hypotensive activity. The peptides are
CC used as hypotensive agents or in health foods, and have favourable taste.
CC The present sequence represents a peptide of the invention, having
CC angiotensin converting enzyme inhibitory activity
SQ Sequence 5 AA;
Query Match 100.0%; Score 27; DB 5; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 TPRVF 5
|||||

```

Db          1 TPRVF 5

RESULT 2
AAR13594
ID AAR13594 standard; peptide; 7 AA.
XX
AC AAR13594;
XX
XX 25-MAR-2003 (revised)
DT 01-NOV-1991 (first entry)
XX
DE Angiotensin converting enzyme inhibitory heptapeptide.
XX
KW Hypertension; soy bean.
XX
OS Glycine max.
XX
PN JP03167198-A.
XX
PD 19-JUL-1991.
XX
PF 24-NOV-1989; 89JP-00303294.
XX
XX 24-NOV-1989; 89JP-00303294.
PR
PA (NORQ ) NORINSHO KK.
XX
XX WPI; 1991-2566668/35.
DR
XX Angiotensin converting enzyme inhibitory substance - comprises hexa and
PT hepta:peptide(s) isolated from soy bean protein, used for treating
PT hypertension as food prod.
XX
XX Claim 1; Page 1; 9pp; Japanese.
PS
XX The peptide and its salts can be used to effectively inhibit the activity
CC of angiotensin converting enzyme. It can be administered as food, since
CC it is safe and free from side effects, being isolated from soy bean
CC protein. It has a mild decreasing effect on blood pressure and may also
CC be used to prevent hypertension. See also AAR13595. (Updated on 25-MAR-
CC 2003 to correct PA field.)
XX
SQ Sequence 7 AA;
Query Match 100.0%; Score 27; DB 2; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 TPRVF 5
          |||||
Db          3 TPRVF 7

RESULT 3
AAB64509
ID AAB64509 standard; protein; 14 AA.
XX
AC AAB64509;
XX
XX 23-MAR-2001 (first entry)
DT
DE Gene 25 human secreted protein homologous amino acid sequence #147.
XX
XX Human; secreted protein; diagnosis; immunosuppressive; antiarthritic;
KW antirheumatic; antiproliferative; cytostatic; cardiant; vasotropic;
KW cerebroprotective; neurotropic; neuroprotective; antibacterial; virucide;
KW fungicide; ophthalmological; autoimmune disease; rheumatoid arthritis;
KW hyperproliferative disorder; neoplasm; cardiovascular disorder;
KW cardiac arrest; cerebrovascular disorder; cerebral ischaemia; infection;
KW angiogenesis; nervous system disorder; Alzheimer's disease; skin aging;
KW ocular disorder; corneal infection; wound healing; food additive;
KW preservative.

XX OS Homo sapiens.
XX WO200077255-A1.
XX 21-DEC-2000.
XX 01-JUN-2000; 2000WO-US014926.
XX 11-JUN-1999; 99US-0138628P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Rosen CA, Ruben SM, Komatsoulis GA;
XX WPI; 2001-025337/03.
DR
XX Isolated nucleic acid molecule encoding a human secreted protein is used
PT in preventing, treating or ameliorating a medical condition.
XX
XX Disclosure; Page 564; 593pp; English.
XX
XX The polynucleotide sequences given in AAF32699 to AAF32747 encode the
CC human secreted proteins given in AAB64422 to AAB64470. AAB64471 to
CC AAB64548 represent human secreted polypeptide sequences and proteins
CC homologous to them, which are given in the exemplification of the present
CC invention. Human secreted proteins have activities based on the tissues
CC and cells the genes are expressed in. Examples of activities include:
CC antiarthritic; immunosuppressive; antirheumatic; antiproliferative;
CC cytostatic; cardiant; vasotropic; cerebroprotective; neurotropic;
CC neuroprotective; antibacterial; virucide; fungicide; and
CC ophthalmological. The polynucleotides and polypeptides can be used to
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. Disorders which are diagnosed or treated include
CC autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC angiogenesis, nervous system disorders e.g. Alzheimer's disease,
CC infections caused by bacteria, viruses and fungi and ocular disorders
CC e.g. corneal infection. The polypeptides can also be used to aid wound
CC healing and epithelial cell proliferation, to prevent skin aging due to
CC sunburn, to maintain organs before transplantation, for supporting cell
CC culture of primary tissues, to regenerate tissues and in chemotaxis. The
CC polypeptides can also be used as a food additive or preservative to
CC increase or decrease storage capabilities. AAF32690 to AAF32698 and
CC AAB64421 represent sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 14 AA;
Query Match 100.0%; Score 27; DB 4; Length 14;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 TPRVF 5
          |||||
Db          4 TPRVF 8

RESULT 4
AAM17754
ID AAM17754 standard; protein; 49 AA.
XX
AC AAM17754;
XX
XX 12-OCT-2001 (first entry)
DT
DE Peptide #4188 encoded by probe for measuring cervical gene expression.
KW Probe; human; microarray; gene expression; cervical epithelial cell;
KW cervical cancer.

```

```

XX OS Homo sapiens.
XX PR WO200157278-A2;
XX PN 09-AUG-2001.
XX PD
XX PP
XX PF 30-JAN-2001; 2001WO-US000670.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 24-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX PP WPI; 2001-488901/53.
XX PR Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human cervical epithelial cells.
XX PS Claim 27; SEQ ID NO 22580; 487pp; English.
XX CC The present invention relates to human single exon nucleic acid probes
XX CC (SENPs; see AAI10068-AAI28459). The present sequence is a peptide encoded
XX CC by one such probe. The SENPs are derived from human HeLa cells. The SENPs
XX CC can be used to produce a single exon microarray, which can be used for
XX CC measuring human gene expression in a sample derived from human cervical
XX CC epithelial cells. By measuring gene expression, the probes are therefore
XX CC useful in grading and/or staging of diseases of the cervix, notably
XX CC cervical cancer. Note: The sequence data for this patent did not form
XX CC part of the printed specification, but was obtained in electronic format
XX CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 49 AA;

Query Match 100.0%; Score 27; DB 4; Length 49;
Best Local Similarity 100.0%; Pred. No. 66;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPRVF 5
Db 19 TPRVF 23

RESULT 5
ABB36778
ID ABB36778 standard; peptide; 49 AA.
XX AC ABB36778;
XX DT 04-FEB-2002 (first entry)
XX DE Peptide #4284 encoded by human foetal liver single exon probe.
XX KW Human; foetal liver; gene expression; single exon nucleic acid probe.
XX OS Homo sapiens.
XX PN WO200157277-A2.
XX PD
XX PP 09-AUG-2001.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.

Query Match 100.0%; Score 27; DB 4; Length 49;
Best Local Similarity 100.0%; Pred. No. 66;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPRVF 5
Db 19 TPRVF 23

RESULT 6
AAM30265
ID AAM30265 standard; protein; 49 AA.
XX AC AAM30265;
XX DT 17-OCT-2001 (first entry)
XX DE Peptide #4302 encoded by probe for measuring placental gene expression.
XX KW Probe; microarray; human; placenta; antenatal diagnosis;
XX KW genetic disorder.
XX OS Homo sapiens.
XX PN WO200157272-A2.
XX PD
XX PP 09-AUG-2001.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 24-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX PP WPI; 2001-48897/53.
XX PR Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human placenta.

```

```

PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX PP WPI; 2001-483447/52.
XX PR Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human fetal liver.
XX PS Claim 27; SEQ ID NO 29413; 639pp + Sequence Listing; English.
XX CC The invention relates to a single exon nucleic acid probe for measuring
XX CC human gene expression in a sample derived from human foetal liver. The
XX CC single exon nucleic acid probes may be used for predicting, measuring and
XX CC displaying gene expression in samples derived from human fetal liver. The
XX CC present sequence is a peptide encoded by a single exon nucleic acid probe
XX CC of the invention. Note: The sequence data for this patent did not form
XX CC part of the printed specification, but was obtained in electronic format
XX CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 49 AA;

Query Match 100.0%; Score 27; DB 4; Length 49;
Best Local Similarity 100.0%; Pred. No. 66;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPRVF 5
Db 19 TPRVF 23

RESULT 6
AAM30265
ID AAM30265 standard; protein; 49 AA.
XX AC AAM30265;
XX DT 17-OCT-2001 (first entry)
XX DE Peptide #4302 encoded by probe for measuring placental gene expression.
XX KW Probe; microarray; human; placenta; antenatal diagnosis;
XX KW genetic disorder.
XX OS Homo sapiens.
XX PN WO200157272-A2.
XX PD
XX PP 09-AUG-2001.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 24-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX PP WPI; 2001-48897/53.
XX PR Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human placenta.

```

Sun Nov 7 14:54:04 2004

XX Claim 27; SEQ ID NO 30534; 654pp; English.

XX The present invention relates to single exon nucleic acid probes (SENP: see AA131315-AA157546). The present sequence is a peptide encoded by one CC such probe. The probes are useful for producing a microarray for CC predicting, measuring and displaying gene expression in samples derived CC from human placenta. The probes are useful for antenatal diagnosis of CC human genetic disorders

XX Sequence 49 AA;

SQ Query Match 100.0%; Score 27; DB 4; Length 49;

Best Local Similarity 100.0%; Pred. NO. 66;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPRVF 5

DB 19 TPRVF 23

RESULT 7

ABB31563

ID ABB31563 standard; peptide; 49 AA.

XX AC ABB31563;

XX 01-FEB-2002 (first entry)

XX Peptide #4214 encoded by breast cell single exon nucleic acid probe.

XX Human; microarray; single exon probe; gene expression; breast; disease; cancer.

XX Homo sapiens.

XX WO200157271-A2.

XX 09-AUG-2001.

XX 30-JAN-2001; 2001WO-US000662.

XX 04-FEB-2000; 2000US-0180312P.

XX 26-MAY-2000; 2000US-0207456P.

XX 30-JUN-2000; 2000US-00608408.

XX 03-AUG-2000; 2000US-00632366.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX WPI; 2001-496933/54.

XX New spatially-addressable set of single exon nucleic acid probes, useful for measuring gene expression in sample derived from human breast, comprises number of single exon nucleic acid probes.

XX Claim 27; SEQ ID NO 14531; 327pp + Sequence Listing; English.

XX The invention relates to a spatially-addressable set of single exon nucleic acid probes for measuring gene expression in a sample derived from human breast and BT 474 cells. The method involves contacting the probes with a collection of detectably labelled nucleic acids derived from mRNA of human breast, and then measuring the label bound to each probe of the microarray. The probes are useful for verifying the expression of regions of genomic DNA predicted to encode proteins. They are useful for gene discovery, and for determining predisposition and/or prognosing breast disease. Gene expression analysis is useful for assessing the toxicity of chemical agents on cells. The microarray of this invention presents a far greater diversity of probes for measuring

CC gene expression, with far less bias than expressed sequence tag microarrays. The method is suitable for rapid production of functional information from genomic sequence. The present sequence is a peptide encoded by a single exon nucleic acid probe of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 49 AA;

SQ Query Match 100.0%; Score 27; DB 4; Length 49;

Best Local Similarity 100.0%; Pred. NO. 66;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TPRVF 5

DB 19 TPRVF 23

RESULT 8

ABB22104

ID ABB22104 standard; protein; 49 AA.

XX AC ABB22104;

XX 23-JAN-2002 (first entry)

XX Protein #4103 encoded by probe for measuring heart cell gene expression.

XX Human; gene expression; heart; microarray; vascular system; cardiovascular disease; hypertension; cardiac arrhythmia; congenital heart disease.

XX Homo sapiens.

XX WO200157274-A2.

XX 09-AUG-2001.

XX 30-JAN-2001; 2001WO-US000666.

XX 04-FEB-2000; 2000US-0180312P.

XX 26-MAY-2000; 2000US-0207456P.

XX 30-JUN-2000; 2000US-00608408.

XX 03-AUG-2000; 2000US-00632366.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX WPI; 2001-488899/53.

XX Single exon nucleic acid probes for analyzing gene expression in human hearts.

XX Claim 15; SEQ ID NO 23874; 530pp; English.

XX The present invention relates to single exon nucleic acid probes for measuring human gene expression in a sample derived from human heart (see ABA21535-ABA41305). The present sequence is a protein encoded by one such probe. The probes may be used for predicting, measuring and displaying gene expression in samples derived from the human heart via microarrays. By measuring gene expression, the probes are useful for predicting, diagnosing, grading, staging, monitoring and prognosing diseases of the human heart and vascular system e.g. cardiovascular disease, hypertension, cardiac arrhythmias and congenital heart disease. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX 30-JAN-2001; 2001WO-US000664.
PF 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-48898/53.
XX Human genome-derived single exon nucleic acid probes useful for analyzing
PT Gene expression in human adult liver.
XX Claim 27; SEQ ID NO 30274; 658pp; English.
XX The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult liver.
CC (I) may be used for predicting, measuring and displaying gene expression
CC in samples derived from human adult liver. The genes identified may be
CC involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC associated with coronary heart disease. ABG47348-ABG59930 represent human
CC liver single exon encoded peptides of the invention. Note: The sequence
CC information for this patent does not appear in the printed specification
CC but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 49 AA;
SQ

Query Match 100.0%; Score 27; DB 4; Length 49;
Best Local Similarity 100.0%; Pred. No. 66;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPRVF 5
| | | | |
Db 19 TPRVF 23

RESULT 12
AAM05410
ID AAM05410 standard; protein; 49 AA.
XX
AC AAM05410;
XX
XX 09-OCT-2001 (first entry)
XX
DE Peptide #4092 encoded by probe for measuring breast gene expression.
XX Probe; human; breast disease; breast cancer; development disorder;
XX inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX Homo sapiens.
XX
XX WO200157270-A2.
XX
XX 09-AUG-2001.
XX
XX 29-JAN-2001; 2001WO-US000661.
XX
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.

PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-476286/51.
XX Novel single exon nucleic acid probe used to measuring gene expression in
XX a human breast.
XX Claim 27; SEQ ID NO 14150; 322pp; English.
XX The present invention relates to novel single exon nucleic acid probes
CC (see AAI00010-AAI10067). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for measuring human gene expression in
CC a human breast sample, where the probe hybridises at high stringency to a
CC nucleic acid expressed in the human breast. The probes are useful for
CC predicting, diagnosing, grading, staging, monitoring and prognosing
CC diseases of the human breast, particularly those diseases with polygenic
CC aetiology. The diseases include: breast cancer, disorders of development,
CC inflammatory diseases of the breast, fibrocystic changes, proliferative,
CC breast disease and non-carcinoma tumours. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 49 AA;
SQ

Query Match 100.0%; Score 27; DB 4; Length 49;
Best Local Similarity 100.0%; Pred. No. 66;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPRVF 5
| | | | |
Db 19 TPRVF 23

RESULT 13
ABG39558
ID ABG39558 standard; peptide; 49 AA.
XX
AC ABG39558;
XX
XX 19-AUG-2002 (first entry)
XX
DE Human peptide encoded by genome-derived single exon probe SEQ ID 29223.
XX
XX Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomatosis; Karagener syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW primary ciliary dyskinesia; pulmonary hypertension;
KW hyaline membrane disease.
XX
XX Homo sapiens.
XX
XX WO200186003-A2.
XX
XX 15-NOV-2001.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 XX (MOLE-) MOLECULAR DYNAMICS INC.
 XX Penn SG, Hanzel DK, Chen W, Rank DR;
 XX WIPI; 2002-114183/15.
 XX Spatially-addressable set of single exon nucleic acid probes, used to
 PT measure gene expression in human lung samples.
 XX Claim 27; SEQ ID NO 29223; 634bp; English.
 CC The invention relates to a spatially-addressable set of single exon
 CC nucleic acid probes for measuring gene expression in a sample derived
 CC from human lung comprising single exon nucleic acid probes having one of
 CC 12614 nucleic acid sequences mentioned in the specification, or their
 CC complements or the 12387 open reading frames derived from the 12614
 CC probes. Also included are a microarray comprising the novel set of probes
 CC; the novel set of probes which hybridize at high stringency to a nucleic
 CC acid expressed in the human lung; measuring gene expression in a sample
 CC derived from human lung, comprising (a) contacting the array with a
 CC collection of detectably labeled nucleic acids derived from human lung
 CC mRNA, and (b) measuring the label detectably bound to each probe of the
 CC array; identifying exons in a eukaryotic genome, comprising (a)
 CC algorithmically predicting at least one exon from genomic sequences of
 CC the eukaryote; and (b) detecting specific hybridisation of detectably
 CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
 CC having a fragment identical to the predicted exon, the probe is included
 CC in the above mentioned microarray; assigning exons to a single gene,
 CC comprising (a) identifying exons from genomic sequence by the method
 CC above and (b) measuring the expression of each of the exons in several
 CC tissues and/or cell types using hybridisation to a single exon
 CC microarrays having a probe with the exon, where a common pattern of
 CC expression of the exons in the tissues and/or cell types indicates that
 CC the exons should be assigned to a single gene; a peptide comprising one
 CC of 12011 sequences, mentioned in the specification, or encoded by the
 CC probes/open reading frames (ORF). The probes are used for gene expression
 CC analysis, and for identifying exons in a gene, particularly using human
 CC lung derived mRNA and for the study of lung diseases such as asthma, lung
 CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
 CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
 CC tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
 CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
 CC histiocytosis, lymphangioleiomyomatosis, pulmonary alveolar proteinosis,
 CC Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
 CC dyskinesia, pulmonary hypertension and hyaline membrane disease. The
 CC present sequence is a peptide/protein encoded by a single exon probe of
 CC the invention. Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 49 AA;
 SQ
 Query Match 100.0%; Score 27; DB 5; Length 49;
 Best Local Similarity 100.0%; Pred. No. 66;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TPRVF 5
 DB 19 TPRVF 23
 RESULT 14
 AAG22500
 ID AAG22500 standard; protein; 65 AA.
 XX AAG22500;
 AC AAG22500;
 XX 17-OCT-2000 (first entry)
 DT Arabidopsis thaliana protein fragment SEQ ID NO: 25452.
 XX Arabidopsis thaliana protein fragment SEQ ID NO: 25452.
 DE

XX Protein identification; signal transduction pathway; metabolic pathway;
 KW hybridisation assay; genetic mapping; gene expression control; promoter;
 KW termination sequence.
 XX Arabidopsis thaliana.
 XX EP1033405-A2.
 XX 06-SEP-2000.
 XX 25-FEB-2000; 2000EP-00301439.
 XX 25-FEB-1999; 99US-0121825P.
 PR 05-MAR-1999; 99US-0123180P.
 PR 09-MAR-1999; 99US-0123548P.
 PR 23-MAR-1999; 99US-0125788P.
 PR 29-MAR-1999; 99US-0126264P.
 PR 01-APR-1999; 99US-0126785P.
 PR 08-APR-1999; 99US-0127462P.
 PR 16-APR-1999; 99US-0128234P.
 PR 19-APR-1999; 99US-0128714P.
 PR 21-APR-1999; 99US-0129845P.
 PR 23-APR-1999; 99US-0130077P.
 PR 28-APR-1999; 99US-0130449P.
 PR 30-APR-1999; 99US-0130510P.
 PR 30-APR-1999; 99US-0130891P.
 PR 04-MAY-1999; 99US-0131449P.
 PR 05-MAY-1999; 99US-0132048P.
 PR 06-MAY-1999; 99US-0132407P.
 PR 07-MAY-1999; 99US-0132484P.
 PR 11-MAY-1999; 99US-0132485P.
 PR 14-MAY-1999; 99US-0132486P.
 PR 14-MAY-1999; 99US-0132487P.
 PR 14-MAY-1999; 99US-0132863P.
 PR 18-MAY-1999; 99US-0133421P.
 PR 18-MAY-1999; 99US-0134219P.
 PR 18-MAY-1999; 99US-0134370P.
 PR 18-MAY-1999; 99US-0134768P.
 PR 19-MAY-1999; 99US-0134941P.
 PR 20-MAY-1999; 99US-0135124P.
 PR 21-MAY-1999; 99US-0135353P.
 PR 24-MAY-1999; 99US-0135629P.
 PR 25-MAY-1999; 99US-0136021P.
 PR 27-MAY-1999; 99US-0136392P.
 PR 28-MAY-1999; 99US-0136782P.
 PR 01-JUN-1999; 99US-0137222P.
 PR 03-JUN-1999; 99US-0137528P.
 PR 04-JUN-1999; 99US-0137502P.
 PR 07-JUN-1999; 99US-0137724P.
 PR 08-JUN-1999; 99US-0138094P.
 PR 10-JUN-1999; 99US-0138540P.
 PR 10-JUN-1999; 99US-0138847P.
 PR 14-JUN-1999; 99US-0139119P.
 PR 16-JUN-1999; 99US-0139452P.
 PR 16-JUN-1999; 99US-0139453P.
 PR 17-JUN-1999; 99US-0139492P.
 PR 18-JUN-1999; 99US-0139454P.
 PR 18-JUN-1999; 99US-0139455P.
 PR 18-JUN-1999; 99US-0139456P.
 PR 18-JUN-1999; 99US-0139457P.
 PR 18-JUN-1999; 99US-0139458P.
 PR 18-JUN-1999; 99US-0139459P.
 PR 18-JUN-1999; 99US-0139460P.
 PR 18-JUN-1999; 99US-0139461P.
 PR 18-JUN-1999; 99US-0139462P.
 PR 18-JUN-1999; 99US-0139463P.
 PR 18-JUN-1999; 99US-0139750P.
 PR 18-JUN-1999; 99US-0139763P.
 PR 21-JUN-1999; 99US-0139817P.
 PR 22-JUN-1999; 99US-0139899P.

us-10-618-644-5.rag

Sun Nov 7 14:54:04 2004

PR 23-JUN-1999;	99US-0140353P.
PR 23-JUN-1999;	99US-0140354P.
PR 24-JUN-1999;	99US-0140695P.
PR 28-JUN-1999;	99US-0140823P.
PR 29-JUN-1999;	99US-0140991P.
PR 30-JUN-1999;	99US-0141287P.
PR 01-JUL-1999;	99US-0141842P.
PR 01-JUL-1999;	99US-0142154P.
PR 02-JUL-1999;	99US-0142055P.
PR 06-JUL-1999;	99US-0142390P.
PR 08-JUL-1999;	99US-0142803P.
PR 09-JUL-1999;	99US-0142920P.
PR 12-JUL-1999;	99US-0142977P.
PR 13-JUL-1999;	99US-0143542P.
PR 14-JUL-1999;	99US-0143624P.
PR 15-JUL-1999;	99US-0144005P.
PR 16-JUL-1999;	99US-0144086P.
PR 18-JUL-1999;	99US-0144325P.
PR 19-JUL-1999;	99US-0144331P.
PR 19-JUL-1999;	99US-0144332P.
PR 19-JUL-1999;	99US-0144333P.
PR 19-JUL-1999;	99US-0144334P.
PR 19-JUL-1999;	99US-0144335P.
PR 20-JUL-1999;	99US-0144352P.
PR 20-JUL-1999;	99US-0144632P.
PR 20-JUL-1999;	99US-0144884P.
PR 21-JUL-1999;	99US-0145086P.
PR 21-JUL-1999;	99US-0145088P.
PR 21-JUL-1999;	99US-0145089P.
PR 22-JUL-1999;	99US-0145087P.
PR 22-JUL-1999;	99US-0145089P.
PR 22-JUL-1999;	99US-0145192P.
PR 22-JUL-1999;	99US-0145145P.
PR 23-JUL-1999;	99US-0145218P.
PR 23-JUL-1999;	99US-0145224P.
PR 26-JUL-1999;	99US-0145276P.
PR 27-JUL-1999;	99US-0145913P.
PR 27-JUL-1999;	99US-0145918P.
PR 27-JUL-1999;	99US-0145919P.
PR 27-JUL-1999;	99US-0145919P.
PR 28-JUL-1999;	99US-0145951P.
PR 02-AUG-1999;	99US-0146386P.
PR 02-AUG-1999;	99US-0146388P.
PR 02-AUG-1999;	99US-0146389P.
PR 03-AUG-1999;	99US-0147038P.
PR 04-AUG-1999;	99US-0147204P.
PR 04-AUG-1999;	99US-0147302P.
PR 05-AUG-1999;	99US-0147192P.
PR 05-AUG-1999;	99US-0147260P.
PR 06-AUG-1999;	99US-0147303P.
PR 06-AUG-1999;	99US-0147416P.
PR 09-AUG-1999;	99US-0147493P.
PR 09-AUG-1999;	99US-0147935P.
PR 09-AUG-1999;	99US-0148171P.
PR 10-AUG-1999;	99US-0148319P.
PR 12-AUG-1999;	99US-0148341P.
PR 13-AUG-1999;	99US-0148565P.
PR 13-AUG-1999;	99US-0148684P.
PR 16-AUG-1999;	99US-0149368P.
PR 17-AUG-1999;	99US-0149175P.
PR 18-AUG-1999;	99US-0149426P.
PR 20-AUG-1999;	99US-0149722P.
PR 20-AUG-1999;	99US-0149723P.
PR 20-AUG-1999;	99US-0149929P.
PR 23-AUG-1999;	99US-0149902P.
PR 23-AUG-1999;	99US-0149930P.
PR 25-AUG-1999;	99US-0150566P.
PR 26-AUG-1999;	99US-0150884P.
PR 27-AUG-1999;	99US-0151065P.
PR 27-AUG-1999;	99US-0151066P.
PR 27-AUG-1999;	99US-0151080P.
PR 30-AUG-1999;	99US-0151303P.
PR 31-AUG-1999;	99US-0151438P.
PR 01-SEP-1999;	99US-0151930P.
PR 07-SEP-1999;	99US-0152363P.
PR 10-SEP-1999;	99US-0153070P.
PR 13-SEP-1999;	99US-0153758P.
PR 15-SEP-1999;	99US-0154018P.
PR 16-SEP-1999;	99US-0154039P.
PR 20-SEP-1999;	99US-0154779P.
PR 22-SEP-1999;	99US-0155133P.
PR 23-SEP-1999;	99US-0155486P.
PR 24-SEP-1999;	99US-0155659P.
PR 28-SEP-1999;	99US-0156458P.
PR 29-SEP-1999;	99US-0156596P.
PR 04-OCT-1999;	99US-0157117P.
PR 05-OCT-1999;	99US-0157753P.
PR 06-OCT-1999;	99US-0157865P.
PR 07-OCT-1999;	99US-0158029P.
PR 08-OCT-1999;	99US-0158232P.
PR 12-OCT-1999;	99US-0158369P.
PR 13-OCT-1999;	99US-0159293P.
PR 13-OCT-1999;	99US-0159294P.
PR 13-OCT-1999;	99US-0159295P.
PR 14-OCT-1999;	99US-0159329P.
PR 14-OCT-1999;	99US-0159330P.
PR 14-OCT-1999;	99US-0159331P.
PR 14-OCT-1999;	99US-0159637P.
PR 14-OCT-1999;	99US-0159638P.
PR 18-OCT-1999;	99US-0159584P.
PR 21-OCT-1999;	99US-0160741P.
PR 21-OCT-1999;	99US-0160767P.
PR 21-OCT-1999;	99US-0160768P.
PR 21-OCT-1999;	99US-0160770P.
PR 21-OCT-1999;	99US-0160814P.
PR 21-OCT-1999;	99US-0160815P.
PR 22-OCT-1999;	99US-0160980P.
PR 22-OCT-1999;	99US-0160981P.
PR 22-OCT-1999;	99US-0160989P.
PR 22-OCT-1999;	99US-0161404P.
PR 25-OCT-1999;	99US-0161405P.
PR 25-OCT-1999;	99US-0161406P.
PR 26-OCT-1999;	99US-0161359P.
PR 26-OCT-1999;	99US-0161360P.
PR 26-OCT-1999;	99US-0161361P.
PR 28-OCT-1999;	99US-0161920P.
PR 28-OCT-1999;	99US-0161992P.
PR 28-OCT-1999;	99US-0161993P.
PR 29-OCT-1999;	99US-0162142P.
Query Match 100.0%; Score 27; DB 3; Length 65;	
Best Local Similarity 100.0%; Pred. No. 88;	
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY 1 TPRVF 5	
Db 21 TPRVF 25	
RESULT 15	
AAM81712	
ID AAM81712 standard; protein; 70 AA.	
XX AC AAM81712;	
XX DT 13-NOV-2001 (first entry)	
XX DE Human haematological malignancy-related antigen #1410.	
XX KW Human; cytostatic; vascular; gene therapy; vaccine; lymphoma;	
XX KW haematological malignancy; antigen; chronic lymphocytic leukaemia;	
XX KW follicular lymphoma; Hodgkin's lymphoma; non-Hodgkin's lymphoma.	
XX OS Homo sapiens.	
XX XX	

PN WO200164886-A2.
XX
PD
XX 07-SEP-2001.
XX
XX 01-MAR-2001; 2001WO-US007272.
XX
XX 01-MAR-2000; 2000US-0186126P.
PR 17-MAR-2000; 2000US-0190479P.
PR 27-APR-2000; 2000US-0200545P.
PR 28-APR-2000; 2000US-0200303P.
PR 28-APR-2000; 2000US-0200779P.
PR 01-MAY-2000; 2000US-0200999P.
PR 04-MAY-2000; 2000US-0202084P.
PR 22-MAY-2000; 2000US-0206201P.
PR 14-JUL-2000; 2000US-0218950P.
PR 03-AUG-2000; 2000US-0222903P.
PR 04-AUG-2000; 2000US-0223416P.
PR 07-AUG-2000; 2000US-0223378P.
XX
XX (CORI-) CORIXA CORP.
XX
XX Gaiger A, Algate PA, Mannion J;
XX
XX WPI; 2001-514842/56.
XX
XX Compositions and methods for the detection of hematological malignancies,
PT e.g. chronic lymphocytic leukemia, lymphoma, follicular lymphoma and
PT Hodgkin's and T/B cell non-Hodgkin's lymphoma.
XX
XX Claim 1; Page 1072-1073; 1252pp; English.
XX
XX The present invention relates to compositions and methods for the
CC detection, diagnosis and therapy of haematological malignancies. The
CC present sequence is the protein sequence of a human haematological
CC malignancy related antigen. The methods of the present invention comprise
CC detecting the presence of haematological malignancy related antigen(s) in
CC a sample obtained from the patient (an increased level of the
CC polypeptide, compared to an unaffected individual, is indicative of an
CC increased risk). Haematological malignancies which can be treated using
CC the present invention are chronic lymphocytic leukaemia, lymphoma,
CC follicular lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma and T/B
CC cell non-Hodgkin's lymphoma
XX
SQ Sequence 70 AA;

Query Match 100.0%; Score 27; DB 4; Length 70;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPRVF 5
Db 54 TPRVF 58

Search completed: November 6, 2004, 19:45:51
Job time : 65.6562 secs

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)